Showing results (81-90 of 215) with videos related to
Sort By:
Pageof 22
Blood Cancer Journal|March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisMeletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.Annals of Hematology|March 8, 2011
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myelomaMarta Krejci, Evzen Gregora, Jan Straub, et al.British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.European Journal of Haematology|October 4, 2015
Cytogenetics in multiple myeloma patients progressing into extramedullary diseaseLenka Besse, Lenka Sedlarikova, Henrieta Greslikova, et al.Blood|October 29, 2008
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myelomaHeinz Ludwig, Roman Hajek, Elena Tóthová, et al.Leukemia Research|April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myelomaPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.Haematologica|July 28, 2011
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patientsSophie L Corthals, Rowan Kuiper, David C Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.Plos One|September 22, 2015
Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary MyelomaLenka Besse, Lenka Sedlarikova, Fedor Kryukov, et al.Bone Marrow Transplantation|November 22, 2018
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myelomaTomas Jelinek, Lucie Adamusova, Tereza Popkova, et al.Pageof 22